Authors
Latest:
A New Approach to Treatment-Resistant C difficile InfectionFecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?
Latest:
What’s New With Non–COVID-19 VaccinesAlthough COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Latest:
What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.
Latest:
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Latest:
Sorry Ganciclovir, You’re Just Not the One for MeImportant clinical considerations to know about resistant CMV infections.
Latest:
HIV and Mpox: Risks, Prevention, and Vaccine AccessIn the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.
Latest:
Key Takeaways on FMTs in the Treatment of CDIExperts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Latest:
Invasive Nontyphoidal Salmonellosis: An Antimicrobial-Resistant FoeSalmonella becomes more dangerous as antimicrobial resistance grows. Read about its most common manifestations.
Latest:
Mixed Fungal Brain AbscessClinicians review a patient case including diagnosis, treatment, and follow-up.
Latest:
Improving Screening, Management of Hepatitis C in Infants and ChildrenDespite hepatitis C (HCV) incidence rates increasing, adequate screening for the virus continues to be a pressing challenge for public health officials.
Latest:
From Poultry to Public Health: Understanding the H5N1 ThreatVeterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.
Latest:
Going Viral on Social Media: Integrating Digital Tools into Pharmacy RotationsIn the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Latest:
The Future and Resources in HCV CareExpert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Latest:
Reducing Peripheral Venous Catheter InfectionsLack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Latest:
Rising Dengue Fever Cases Carry One Health ImplicationsThe increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.
Latest:
The Yin and Yang of Ceftolozane-Tazobactam Resistance Against Multidrug-Resistant Pseudomonas aeruginosaRates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.
Latest:
Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii PneumoniaHere is a review of using this therapy in this patient population.
Latest:
What’s New in 2023 From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThis year's Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing provided updated breakpoints on therapies.
Latest:
Long-Acting Injectables for the Prevention or Treatment of HIVIn the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.
Latest:
Where Do We Draw the Line? Duration of Antibiotic Therapy Varies for Bloodstream InfectionsWith potential delays in treatment, bloodstream infections can be concerning for clinicians. Here is a review of the literature that offer guidance for treatment.
Latest:
COVID-19 Roundtable: Should Clinicians Consider Off Label COVID Therapies?In this week's episode, the panel weighs in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.
Latest:
The Future and Resources in HCV CareExpert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Latest:
A Case of Candida Albicans Ventriculitis Secondary to E Coli Ventriculoperitoneal Shunt InfectionRare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.
Latest:
Challenges in the Management of Mycobacterium abscessus ComplexThis pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Latest:
Optimizing ART for Patients With a History of Treatment Failure and ResistanceA review of treatment modalities for this patient population.
Latest:
Lessons in Resilience: What HIV Teaches Us About COVID-19Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
Latest:
Advice for Physicians to Manage C. Difficile Infection (CDI)Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
Latest:
Sulbactam for Treatment of Carbapenem-Resistant Acinetobacter baumanniiThis is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.
